Longer follow-up confirms improved overall survival

首页> 外文期刊>Prescrire international >Longer follow-up confirms improved overall survival

【24h】

Longer follow-up confirms improved overall survival

机译：更长的随访时间证实了总生存期的改善

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Adjuvant cytotoxic chemotherapy following surgical treatment of non-metastatic breast cancer usually includes an anthracycline.The addition of trastuzumab should be considered for women whose tumours over-express HER-2 protein. Trastuzumab has been approved in the European Union since 2006 for adjuvant treatment of breast cancer. In 2011, the indications were further specified to allow the use of adjuvant trastuzumab in both anthracycline-based and non-anthracycline protocols. In 2006, the results of the first 3 trials of adjuvant chemotherapy showed an absolute gain in overall survival of about 4% after 4 years with trastuzumab. Updates of these trials, with longer follow-up, along with the results of a fourth trial, confirm the overall survival benefit, whether or not the adjuvant regimen includes an anthracycline (about 91% versus 87%). 285

机译：非转移性乳腺癌手术治疗后的辅助细胞毒性化疗通常包括蒽环类药物。对于肿瘤过表达HER-2蛋白的女性，应考虑加入曲妥珠单抗。自2006年以来，曲妥珠单抗已获欧盟批准用于乳腺癌的辅助治疗。 2011年，进一步明确了适应症，以允许在基于蒽环类和非蒽环类药物的方案中使用曲妥珠单抗辅助剂。 2006年，前3项辅助化疗试验的结果显示，曲妥珠单抗治疗4年后，总生存率绝对增加约4％。这些试验的更新以及更长的随访时间以及第四次试验的结果，证实了总体生存获益，无论辅助方案是否包括蒽环类药物（约91％比87％）。 285

著录项

来源
《Prescrire international》 |2012年第133期|共3页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. Longer follow-up confirms improved overall survival [J] . Prescrire international . 2012,第133期

机译：更长的随访时间证实了总生存期的改善
2. An Analysis of Real Life Data Obtained from 30 Years Follow-up of Primary Myelodysplastic Syndromes (MDS) Patients Confirms a Leading Role of Stem Cell Transplantation (SCT) for Achievement of Prolonged Survival [J] . Cermak Jaroslav, Vitek Antonin, Mikulenkova Dana, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：从30年的原发性髓细胞增强综合征（MDS）患者随访的现实生活数据分析证实干细胞移植（SCT）实现长期生存的主要作用
3. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. [J] . Piccart MJ, Stuart G, Mangioni C, International journal of gynecological cancer: official journal of the International Gynecological Cancer Society . 2003,第Suppla2期

机译：长期随访证实，在晚期卵巢癌中，紫杉醇-顺铂方案相对于环磷酰胺-顺铂方案具有生存优势。
4. SHORT-TERM TUMOR RESPONSE TO TYROSINE KINASE INHIBITORS VERSUS LONG-TERM SURVIVAL IN MAST CELL TUMORS: FOLLOW-UP DATA FROM A PIVOTAL FIELD STUDY WITH MASITINIB [C] . Olivier Hermine Annual Conference of the Veterinary Cancer Society . 2009

机译：短期肿瘤对酪氨酸激酶抑制剂的反应与肥大细胞肿瘤的长期存活：来自Masitinib的关键田间研究的后续数据
5. Development and Evaluation of an Occupational Health Nurse Practitioner-Directed Evaluation, Referral, and Follow-Up Program to Improve Treatment Compliance among Patients with Uncontrolled Hypertension [D] . Bothe, Noelle M. 2019

机译：开发和评估职业健康护士从业者执导的评估，转诊和后续计划，以改善不受控制的高血压患者的治疗顺应性
6. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma [O] . Axel Hauschild, Reinhard Dummer, Dirk Schadendorf, -1

机译：更长的随访时间证实BRAF V600–Mutant III期恶性黑色素瘤切除术后辅佐达拉非尼+曲美替尼可无复发生存
7. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma [O] . Axel Hauschild, Reinhard Dummer, Dirk Schadendorf, 2018

机译：更长的随访证实复发的生存益处与佐剂Dabrafenib Plus Trametinib患者在切除的BRAF V600-突变阶段III黑色素瘤中

Longer follow-up confirms improved overall survival

摘要

著录项

相似文献

相关主题

期刊订阅